Hangzhou Innogate Pharma Co. Ltd. has identified kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer and viral infections.
Coherent Biopharma Ltd. has divulged peptide-drug conjugates comprising cytotoxic drug covalently linked to folate receptor α (FOLR1; FR- α)-targeting moiety through linker reported to be useful for the treatment of cancer and metabolic, immunological and neurological disorders.
The alpha chain of the IL-3 receptor, CD123, is frequently overexpressed in acute myeloid leukemia (AML) and is considered an attractive target in the treatment of this disease. However, cytotoxic antibodies or T-cell engagers targeting CD123 have shown insufficient clinical efficacy or safety, confirming the need for alternative targeted approaches.
Three Aurora kinases (AURKA, AURKB and AURKC) are required for cell division and their activities/expression is increased in many human cancers. Accordingly, AURK inhibitors have entered early clinical trials, but their approval has been delayed due to off-target dose-limiting toxicity. Inhibition of AURKB catalytic activity is distinguished in that does not depend on disruption of spindle microtubules, but targeting catalytic activity disables both mitotic and nondividing cells.
The FDA has awarded rare pediatric disease designation to Orphagen Pharmaceuticals Inc.'s OR-449 for the treatment of pediatric adrenocortical carcinoma (ACC). OR-449 is a selective, first-in-class, potent and orally bioavailable small-molecule antagonist to steroidogenic factor-1 (SF-1; NR5A1), an orphan nuclear receptor and transcription factor that is essential for the growth and development of the adrenal gland.
Maia Biotechnology Inc. has advanced its telomere-targeting molecule program (Project T3) with the nomination of a lead new molecular entity candidate (MAIA-2021-20) and a back-up new molecular entity candidate (MAIA-2022-12) for progression into preclinical GLP-toxicity and other studies. One of these candidates may then be advanced into clinical trials upon completion of the preclinical evaluations.
Being able to detect cancers early can substantially improve survival, but most early detection tests for cancer rely on expensive and sophisticated molecular techniques that might be difficult to implement in resource strapped environments. Two new studies published last week attempt to overcome this problem.
Fochon Biosciences Ltd. has disclosed mitogen-activated protein kinase (ERK) inhibitors, particularly ERK1 and/or ERK2 reported to be useful for the treatment of cancer.
Immunos Therapeutics AG has received full ethical institutional approval from the Human Research Ethics Committee (HREC) and regulatory approval from the Australian Therapeutic Goods Administration (TGA) to conduct a phase I trial of its lead program IOS-1002 in Australia.
Major histocompatibility complex class I (MHC-I) gene promoters are bivalently modified during development, which can be exploited in cancer cells to silence MHC-I expression and evade CD8+ T cells; in cells that exhibit bivalent modification of MHC-I genes, lower levels of cell surface MHC-I can be induced either by PRC2 inhibition or exposing the cells to interferon γ (IFNγ) in conjunction with polycomb inhibition to allow a permissive chromatin status.
RSS
.webp?height=488&t=1670008838&width=650 "Acute myeloid leukemia")
